## Drug Summary
Flecainide, also marketed under the names Almarytm and Apocard, is a class Ic antiarrhythmic drug primarily used to manage supraventricular and ventricular arrhythmias, and to prevent episodes of paroxysmal atrial fibrillation and flutter. Flecainide blocks sodium and potassium ion channels, thus increasing the threshold for depolarization and prolonging action potential duration, particularly in ventricular muscle fibers and Purkinje fibers. These effects help to maintain a regular heart rhythm. Flecainide is characterized by a high bioavailability of 90%, reaching peak plasma concentrations within 3-4 hours following oral administration. It has a long duration of action, which supports once-daily dosing, but it has a narrow therapeutic index that requires careful dosing and monitoring, especially in patients with structural heart disease or systolic dysfunction.

## Drug Targets, Enzymes, Transporters, and Carriers
Flecainide acts on various cardiac ion channels and receptors which include SCN4A and SCN5A (sodium channels), KCNH2 (potassium channels), and RYR2 (ryanodine receptors). Blocking these channels contributes to the alteration of electrical conduction through the heart. It is metabolized in the liver primarily through the enzymes CYP2D6, CYP1A2, and CYP2C9 into less active metabolites. Additionally, the drug interacts with transporters such as ABCB1 (P-glycoprotein 1) and SLC47A1 (multidrug and toxin extrusion protein 1), and is carried by proteins including ORM2 (alpha1-acid glycoprotein) and ALB (serum albumin), which may affect its pharmacokinetics and pharmacodynamics.

## Pharmacogenetics
Flecainideâ€™s metabolism by CYP2D6 is of particular interest in pharmacogenetics. Variations in the CYP2D6 gene can lead to different metabolic phenotypes ranging from poor metabolizers to ultra-rapid metabolizers. This variability may significantly influence the drug's plasma levels and its efficacy or toxicity. Poor metabolizers might experience higher plasma levels, resulting in an increased risk for toxicity, while ultra-rapid metabolizers could have reduced efficacy due to faster drug clearance. Therefore, genetic testing for CYP2D6 variants may be useful in personalizing Flecainide therapy for optimal efficacy and safety. The presence of such genetic interactions, inferences based on current pharmacogenomic knowledge, means that personalized dosing recommendations could potentially improve therapeutic outcomes and minimize adverse effects in patients taking flecainide.